TScan Therapeutics Announces First Patient Dosed in Phase 3
TScan Therapeutics announced the dosing of the first patient in its pivotal Phase 3 ALLOHA-2™ trial for TSC-101. This study evaluates TSC-101 for preventing relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic cell transplantation. The company expects …